The blood-brain barrier challenge for the treatment of brain cancer, secondary brain metastases, and neurological diseases

Cancer Genomics and Proteomics

Volumn 12, Issue 4, 2015, Pages 167-178

  Weidle, Ulrich H ^a   Niewohner, Jens ^a   Tiefenthaler, Georg ^a  

^a ROCHE INNOVATION CENTER MUNICH   (Germany)

Author keywords

Animal metastasis models; Antibody antibody fusion; Antibody effector protein fusion; Insulin receptor; Molecular Trojan horses; Receptor mediated endocytosis; Review; Transferrin receptor; Tropism of metastasis

Indexed keywords

AFATINIB; BEVACIZUMAB; CARBOPLATIN; CRIZOTINIB; DABRAFENIB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; EVEROLIMUS; GEFITINIB; HYBRID PROTEIN; INIPARIB; IPILIMUMAB; IRBINITINIB; IRINOTECAN; LAPATINIB; LEVO IDURONIDASE; LIATERMIN; NERATINIB; OLAPARIB; PACLITAXEL; PROCARBAZINE; RECOMBINANT ERYTHROPOIETIN; TEMOZOLOMIDE; TOPOTECAN; TRASTUZUMAB; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN ANTIBODY; VELIPARIB; VORINOSTAT; MOLECULAR LIBRARY;

ACTIVE TRANSPORT; ADVANCED CANCER; ANGIOGENESIS; ARTICLE; ASTROCYTE; BLOOD BRAIN BARRIER; BRAIN CANCER; BRAIN CELL; BRAIN METASTASIS; BRAIN TUMOR; BREAST CANCER; CANCER MODEL; CEREBROVASCULAR ACCIDENT; CLINICAL STUDY; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG TRANSPORT; DRUG UPTAKE; ENDOCYTOSIS; EXOCYTOSIS; HUMAN; HURLER SYNDROME; INTRACELLULAR TRANSPORT; METASTASIS INHIBITION; MICROMETASTASIS; MOLECULAR SIZE; MOLECULARLY TARGETED THERAPY; NEUROLOGIC DISEASE; NONHUMAN; PARKINSON DISEASE; PERICYTE; PROTEIN TRANSPORT; TRANSCYTOSIS; TRIPLE NEGATIVE BREAST CANCER; TUMOR MICROENVIRONMENT; UPREGULATION; WHOLE BODY RADIATION; ANIMAL; BRAIN NEOPLASMS; DISEASE MODEL; DRUG EFFECTS; METASTASIS; MOLECULAR LIBRARY; PATHOLOGY; THERAPEUTIC USE;

ANIMALIA; EQUIDAE;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASM METASTASIS; SMALL MOLECULE LIBRARIES;

EID: 84939243926     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Article

References (122)

1. Marchesi V: CNS cancer: metabolic changes in brain tumors. Nat Rev Clin Oncol 10: 607, 2013.
2. Fidler I and Ellis LM: The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 79: 185-188, 1994.
3. Poste G and Fidler IJ: The pathogenesis of cancer metastasis. Nature 283: 139-146, 1980.
4. Nguyen DX and Massague J: Genetic determinants of cancer metastasis. Nat Rev Genet 8: 341-352, 2007.
5. Vogelstein B and Kinzler KW: Cancer genes and the pathways they control. Nat Med 10: 789-799, 2004.
6. Brabletz T: To differentiate or not-routes towards metastasis. Nat Rev Cancer 12: 425-436, 2012.
7. Weigelt B, Peterse JL and van 't Veer LJ: Breast cancer metastasis: markers and models. Nat Rev Cancer 5: 591-602, 2005.
8. MacDonald NJ and Steeg PS: Molecular basis of tumour metastasis. Cancer Surv 16: 175-199, 1993.
9. Chambers AF, MacDonald IC, Schmidt EE, Morris VL and Groom AC: Clinical targets for anti-metastasis therapy. Adv Cancer Res 79: 91-121, 2000.
10. Nathoo N, Chahlavi A, Barnett GH and Toms SA: Pathobiology of brain metastases. J Clin Pathol 58: 237-242, 2005.
11. Pardridge WM: Drug and gene targeting to the brain with molecular Trojan horses. Nat Rev Drug Discov 1: 131-139, 2002.
12. Laquintana V, Trapani A, Denora N, Wang F, Gallo JM and Trapani G: New strategies to deliver anticancer drugs to brain tumors. Expert Opin Drug Deliv 6: 1017-1032, 2009.
13. Chacko AM, Li C, Pryma DA, Brem S, Coukos G and Muzykantov V: Targeted delivery of antibody-based therapeutic and imaging agents to CNS tumors: crossing the blood-brain barrier divide. Expert Opin Drug Deliv 10: 907-926, 2013.
14. Giragossian C, Clark T, Piche-Nicholas N and Bowman CJ: Neonatal Fc receptor and its role in the absorption, distribution, metabolism and excretion of immunoglobulin G-based biotherapeutics. Curr Drug Metab 14: 764-790, 2013.
15. Mathieu D and Fortin D: Chemotherapy and delivery in the treatment of primary brain tumors. Curr Clin Pharmacol 2: 197-211, 2007.
16. Jia W, Lu R, Martin TA and Jiang WG: The role of claudin-5 in blood-brain barrier (BBB) and brain metastases (review). Mol Med Rep 9: 779-785, 2014.
17. Correale J and Villa A: Cellular elements of the blood-brain barrier. Neurochem Res 34: 2067-2077, 2009.
18. Pardridge WM: Receptor-mediated peptide transport through the blood-brain barrier. Endocr Rev 7: 314-330, 1986.
19. Pardridge WM: Blood-brain barrier drug targeting: the future of brain drug development. Mol Interv 3: 90-105, 2003.
20. Hediger MA, Romero MF, Peng JB, Rolfs A, Takanaga H and Bruford EA: The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteins. Introduction. Pflugers Arch 447: 465-468, 2004.
21. Demeule M, Regina A, Jodoin J, Laplante A, Dagenais C, Berthelet F, Moghrabi A and Beliveau R: Drug transport to the brain: key roles for the efflux pump P-glycoprotein in the blood-brain barrier. Vascul Pharmacol 38: 339-348, 2002.
22. Huang Y and Sadee W: Membrane transporters and channels in chemoresistance and-sensitivity of tumor cells. Cancer Lett 239: 168-182, 2006.
23. Kruh GD and Belinsky MG: The MRP family of drug efflux pumps. Oncogene 22: 7537-7552, 2003.
24. Dufes C, A Robaian M and Somani S: Transferrin and the transferrin receptor for the targeted delivery of therapeutic agents to the brain and cancer cells. Ther Deliv 4: 629-640, 2013.
25. EL Andaloussi S, Mager I, Breakefield XO and Wood MJ: Extracellular vesicles: biology and emerging therapeutic opportunities. Nat Rev Drug Discov 12: 347-357, 2013.
26. Salama NN, Eddington ND and Fasano A: Tight junction modulation and its relationship to drug delivery. Adv Drug Deliv Rev 58: 15-28, 2006.
27. Smith MW and Gumbleton M: Endocytosis at the blood-brain barrier: from basic understanding to drug delivery strategies. J Drug Target 14: 191-214, 2006.
28. Kienast Y, von Baumgarten L, Fuhrmann M, Klinkert WE, Goldbrunner R, Herms J and Winkler F: Real-time imaging reveals the single steps of brain metastasis formation. Nat Med 16: 116-122, 2010.
29. Carbonell WS, Ansorge O, Sibson N and Muschel R: The vascular basement membrane as "soil" in brain metastasis. PLoS One 4: e5857, 2009.
30. Heyn C, Ronald JA, Mackenzie LT, MacDonald IC, Chambers AF, Rutt BK and Foster PJ: In vivo magnetic resonance imaging of single cells in mouse brain with optical validation. Magn Reson Med 55: 23-29, 2006.
31. Fidler IJ: Selection of successive tumour lines for metastasis. Nat New Biol 242: 148-149, 1973.
32. Brunson KW, Beattie G and Nicolsin GL: Selection and altered properties of brain-colonising metastatic melanoma. Nature 272: 543-545, 1978.
33. Schackert G and Fidler IJ: Site-specific metastasis of mouse melanomas and a fibrosarcoma in the brain or meninges of syngeneic animals. Cancer Res 48: 3478-3484, 1988.
34. Fidler IJ: The role of the organ microenvironment in brain metastasis. Semin Cancer Biol 21: 107-112, 2011.
35. Cruz-Munoz W, Man S, Xu P and Kerbel RS: Development of a preclinical model of spontaneous human melanoma central nervous system metastasis. Cancer Res 68: 4500-4505, 2008.
36. Daphu I, Sundstrom T, Horn S, Huszthy PC, Niclou SP, Sakariassen PO, Immervoll H, Miletic H, Bjerkvig R and Thorsen F: In vivo animal models for studying brain metastasis: value and limitations. Clin Exp Metastasis 30: 695-710, 2013.
37. Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, Nguyen DX, Minn AJ, van de Vijver MJ, Gerald WL, Foekens JA and Massague J: Genes that mediate breast cancer metastasis to the brain. Nature 459: 1005-1009, 2009.
38. Lockman PR, Mittapalli RK, Taskar KS, Rudraraju V, Gril B, Bohn KA, Adkins CE, Roberts A, Thorsheim HR, Gaasch JA, Huang S, Palmieri D, Steeg PS and Smith QR: Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin Cancer Res 16: 5664-5678, 2010.
39. Fitzgerald DP, Palmieri D, Hua E, Hargrave E, Herring JM, Qian Y, Vega-Valle E, Weil RJ, Stark AM, Vortmeyer AO and Steeg PS: Reactive glia are recruited by highly proliferative brain metastases of breast cancer and promote tumor cell colonization. Clin Exp Metastasis 25: 799-810, 2008.
40. Palmieri D, Bronder JL, Herring JM, Yoneda T, Weil RJ, Stark AM, Kurek R, Vega-Valle E, Feigenbaum L, Halverson D, Vortmeyer AO, Steinberg SM, Aldape K and Steeg PS: HER2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. Cancer Res 67: 4190-4198, 2007.
41. Gril B, Palmieri D, Bronder JL, Herring JM, Vega-Valle E, Feigenbaum L, Liewehr DJ, Steinberg SM, Merino MJ, Rubin SD and Steeg PS: Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J Natl Cancer Inst 100: 1092-1103, 2008.
42. Steeg PS, Camphausen KA and Smith QR: Brain metastases as preventive and therapeutic targets. Nat Rev Cancer 11: 352-363, 2011.
43. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Olshen AB, Gerald WL and Massague J: Genes that mediate breast cancer metastasis to lung. Nature 436: 518-524, 2005.
44. Gupta GP, Nguyen DX, Chiang AC, Bos PD, Kim JY, Nadal C, Gomis RR, Manova-Todorova K and Massague J: Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature 446: 765-770, 2007.
45. Palmieri D, Fitzgerald D, Shreeve SM, Hua E, Bronder JL, Weil RJ, Davis S, Stark AM, Merino MJ, Kurek R, Mehdorn HM, Davis G, Steinberg SM, Meltzer PS, Aldape K and Steeg PS: Analyses of resected human brain metastases of breast cancer reveal the association between up-regulation of hexokinase 2 and poor prognosis. Mol Cancer Res 7: 1438-1445, 2009.
46. Hinton CV, Avraham S and Avraham HK: Role of the CXCR4/CXCL12 signaling axis in breast cancer metastasis to the brain. Clin Exp Metastasis 27: 97-105, 2010.
47. Nam DH, Jeon HM, Kim S, Kim MH, Lee YJ, Lee MS, Kim H, Joo KM, Lee DS, Price JE, Bang SI and Park WY: Activation of notch signaling in a xenograft model of brain metastasis. Clin Cancer Res 14: 4059-4066, 2008.
48. Adamo B, Deal AM, Burrows E, Geradts J, Hamilton E, Blackwell KL, Livasy C, Fritchie K, Prat A, Harrell JC, Ewend MG, Carey LA, Miller CR and Anders CK: Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases. Breast Cancer Res 13: R125, 2011.
49. Zhang C, Zhang F, Tsan R and Fidler IJ: Transforming growth factor-beta2 is a molecular determinant for site-specific melanoma metastasis in the brain. Cancer Res 69: 828-835, 2009.
50. Xie TX, Huang FJ, Aldape KD, Kang SH, Liu M, Gershenwald JE, Xie K, Sawaya R and Huang S: Activation of STAT3 in human melanoma promotes brain metastasis. Cancer Res 66: 3188-3196, 2006.
51. Palmieri D, Lockman PR, Thomas FC, Hua E, Herring J, Hargrave E, Johnson M, Flores N, Qian Y, Vega-Valle E, Taskar KS, Rudraraju V, Mittapalli RK, Gaasch JA, Bohn KA, Thorsheim HR, Liewehr DJ, Davis S, Reilly JF, Walker R, Bronder JL, Feigenbaum L, Steinberg SM, Camphausen K, Meltzer PS, Richon VM, Smith QR and Steeg PS: Vorinostat inhibits brain metastatic colonization in a model of triplenegative breast cancer and induces DNA double-strand breaks. Clin Cancer Res 15: 6148-6157, 2009.
52. Baschnagel A, Russo A, Burgan WE, Carter D, Beam K, Palmieri D, Steeg PS, Tofilon P and Camphausen K: Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown in vitro and as intracranial xenografts. Mol Cancer Ther 8: 1589-1595, 2009.
53. Kim LS, Huang S, Lu W, Lev DC and Price JE: Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastases in nude mice. Clin Exp Metastasis 21: 107-118, 2004.
54. Jain RK: Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7: 987-989, 2001.
55. Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, Xu L, Hicklin DJ, Fukumura D, di Tomaso E, Munn LL and Jain RK: Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6: 553-563, 2004.
56. Leenders WP, Kusters B, Verrijp K, Maass C, Wesseling P, Heerschap A, Ruiter D, Ryan A and de Waal R: Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option. Clin Cancer Res 10: 6222-6230, 2004.
57. Kodack DP, Chung E, Yamashita H, Incio J, Duyverman AM, Song Y, Farrar CT, Huang Y, Ager E, Kamoun W, Goel S, Snuderl M, Lussiez A, Hiddingh L, Mahmood S, Tannous BA, Eichler AF, Fukumura D, Engelman JA and Jain RK: Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases. Proc Natl Acad Sci USA 109: E3119-3127, 2012.
58. Nieder C, Spanne O, Mehta MP, Grosu AL and Geinitz H: Presentation, patterns of care, and survival in patients with brain metastases: what has changed in the last 20 years? Cancer 117: 2505-2512, 2011.
59. Owonikoko TK, Arbiser J, Zelnak A, Shu HK, Shim H, Robin AM, Kalkanis SN, Whitsett TG, Salhia B, Tran NL, Ryken T, Moore MK, Egan KM and Olson JJ: Current approaches to the treatment of metastatic brain tumours. Nat Rev Clin Oncol 11: 203-222, 2014.
60. Thomas FC, Taskar K, Rudraraju V, Goda S, Thorsheim HR, Gaasch JA, Mittapalli RK, Palmieri D, Steeg PS, Lockman PR and Smith QR: Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer. Pharm Res 26: 2486-2494, 2009.
61. Sun M, Behrens C, Feng L, Ozburn N, Tang X, Yin G, Komaki R, Varella-Garcia M, Hong WK, Aldape KD and Wistuba II: HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors. Clin Cancer Res 15: 4829-4837, 2009.
62. Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, Wu YL, Thomas M, O'Byrne KJ, Moro-Sibilot D, Camidge DR, Mok T, Hirsh V, Riely GJ, Iyer S, Tassell V, Polli A, Wilner KD and Janne PA: Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368: 2385-2394, 2013.
63. Solomon B, Wilner KD2 and Shaw AT3: Current status of targeted therapy for anaplastic lymphoma kinase-rearranged non-small cell lung cancer. Clin Pharmacol Ther 95: 15-23, 2014.
64. Chuan Tang S, Nguyen LN, Sparidans RW, Wagenaar E, Beijnen JH and Schinkel AH: Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Int J Cancer 134: 1484-1494, 2014.
65. Byrne TN, Cascino TL and Posner JB: Brain metastasis from melanoma. J Neurooncol 1: 313-317, 1983.
66. Davies MA, Stemke-Hale K, Lin E, Tellez C, Deng W, Gopal YN, Woodman SE, Calderone TC, Ju Z, Lazar AJ, Prieto VG, Aldape K, Mills GB and Gershenwald JE: Integrated molecular and clinical analysis of AKT activation in metastatic melanoma. Clin Cancer Res 15: 7538-7546, 2009.
67. Eichler AF, Chung E, Kodack DP, Loeffler JS, Fukumura D and Jain RK: The biology of brain metastases-translation to new therapies. Nat Rev Clin Oncol 8: 344-56, 2011.
68. Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP, Hamid O, Infante JR, Millward M, Pavlick AC, O'Day SJ, Blackman SC, Curtis CM, Lebowitz P, Ma B, Ouellet D and Kefford RF: Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase I dose-escalation trial. Lancet 379: 1893-1901, 2012.
69. Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, Puzanov I, Hauschild A, Robert C, Algazi A, Mortier L, Tawbi H, Wilhelm T, Zimmer L, Switzky J, Swann S, Martin AM, Guckert M, Goodman V, Streit M, Kirkwood JM and Schadendorf D: Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 13: 1087-1095, 2012.
70. Della Vittoria Scarpati G, Fusciello C, Perri F, Sabbatino F, Ferrone S, Carlomagno C and Pepe S: Ipilimumab in the treatment of metastatic melanoma: management of adverse events. Onco Targets Ther 7: 203-209, 2014.
71. Lin NU, Amiri-Kordestani L, Palmieri D, Liewehr DJ and Steeg PS: CNS metastases in breast cancer: old challenge, new frontiers. Clin Cancer Res 19: 6404-6418, 2013.
72. Olson EM, Abdel-Rasoul M, Maly J, Wu CS, Lin NU and Shapiro CL: Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab. Ann Oncol 24: 1526-1533, 2013.
73. Pestalozzi BC, Holmes E, de Azambuja E, Metzger-Filho O, Hogge L, Scullion M, Lang I, Wardley A, Lichinitser M, Sanchez RI, Muller V, Dodwell D, Gelber RD, Piccart-Gebhart MJ and Cameron D: CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01). Lancet Oncol 14: 244-248, 2013.
74. Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I, Bunnell C, Rue M, Gelman R and Winer E: Central nervous system metastases in women who receive trastuzumabbased therapy for metastatic breast carcinoma. Cancer 97: 2972-2977, 2003.
75. Dijkers EC, Oude Munnink TH, Kosterink JG, Brouwers AH, Jager PL, de Jong JR, van Dongen GA, Schroder CP, Lub-de Hooge MN and de Vries EG: Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther 87: 586-592, 2010.
76. Ningaraj NS: Drug delivery to brain tumours: challenges and progress. Expert Opin Drug Deliv 3: 499-509, 2006.
77. Poduslo JF, Curran GL and Berg CT: Macromolecular permeability across the blood-nerve and blood-brain barriers. Proc Natl Acad Sci USA 91: 5705-5709, 1994.
78. Felgenhauer K: Protein size and cerebrospinal fluid composition. Klin Wochenschr 52: 1158-1164, 1974.
79. Lee J, Lund-Smith C, Borboa A, Gonzalez AM, Baird A and Eliceiri BP: Glioma-induced remodeling of the neurovascular unit. Brain Res 1288: 125-134, 2009.
80. DeLuca I, Blachere NE, Santomasso B and Darnell RB: Tolerance to the neuron-specific paraneoplastic HuD antigen. PLoS One 4: e5739, 2009.
81. Heimberger AB, Suki D, Yang D, Shi W and Aldape K: The natural history of EGFR and EGFRvIII in glioblastoma patients. J Transl Med 3: 38, 2005.
82. Kuan CT, Wikstrand CJ and Bigner DD: EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr Relat Cancer 8: 83-96, 2001.
83. Sivasankaran B, Degen M, Ghaffari A, Hegi ME, Hamou MF, Ionescu MC, Zweifel C, Tolnay M, Wasner M, Mergenthaler S, Miserez AR, Kiss R, Lino MM, Merlo A, Chiquet-Ehrismann R and Boulay JL: Tenascin-C is a novel RBPJκ-induced target gene for Notch signaling in gliomas. Cancer Res 69: 458-465, 2009.
84. Zalutsky MR, Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, McLendon RE, Wong TZ and Bigner DD: Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med 49: 30-38, 2008.
85. Reardon DA, Zalutsky MR, Akabani G, Coleman RE, Friedman AH, Herndon JE 2nd, McLendon RE, Pegram CN, Quinn JA, Rich JN, Vredenburgh JJ, Desjardins A, Guruangan S, Boulton S, Raynor RH, Dowell JM, Wong TZ, Zhao XG, Friedman HS and Bigner DD: A pilot study: 131I-antitenascin monoclonal antibody 81C6 to deliver a 44-Gy resection cavity boost. Neuro Oncol 10: 182-189, 2008.
86. Hernandez-Pedro NY, Rangel-Lopez E, Vargas Felix G, Pineda B and Sotelo J: An update in the use of antibodies to treat glioblastoma multiforme. Autoimmune Dis 2013: 716813, 2013.
87. Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, Wolchok JD, Clark JI, Sznol M, Logan TF, Richards J, Michener T, Balogh A, Heller KN and Hodi FS: Ipilimumab in patients with melanoma and brain metastases: an open-label, phase II trial. Lancet Oncol 13: 459-465, 2012.
88. Kingsley DP: An interesting case of possible abscopal effect in malignant melanoma. Br J Radiol 48: 863-866, 1975.
89. Stamell EF, Wolchok JD, Gnjatic S, Lee NY and Brownell I: The abscopal effect associated with a systemic anti-melanoma immune response. Int J Radiat Oncol Biol Phys 85: 293-295, 2013.
90. Pardridge WM1 and Boado RJ: Re-engineering biopharmaceuticals for targeted delivery across the blood-brain barrier. Methods Enzymol 503: 269-292, 2012.
91. Pardridge WM: Drug transport across the blood-brain barrier. J Cereb Blood Flow Metab 32: 1959-1972, 2012.
92. Pardridge WM, Eisenberg J and Yang J: Human blood-brain barrier transferrin receptor. Metabolism 36: 892-895, 1987.
93. Friden PM, Walus LR, Musso GF, Taylor MA, Malfroy B and Starzyk RM: Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier. Proc Natl Acad Sci USA 88: 4771-4775, 1991.
94. Pardridge WM, Buciak JL and Friden PM: Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo. J Pharmacol Exp Ther 259: 66-70, 1991.
95. Lee HJ, Engelhardt B, Lesley J, Bickel U and Pardridge WM: Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood-brain barrier in mouse. J Pharmacol Exp Ther 292: 1048-1052, 2000.
96. Kissel K, Hamm S, Schulz M, Vecchi A, Garlanda C and Engelhardt B: Immunohistochemical localization of the murine transferrin receptor (TfR) on blood-tissue barriers using a novel anti-TfR monoclonal antibody. Histochem Cell Biol 110: 63-72, 1998.
97. Lee HJ, Zhang Y, Zhu C, Duff K and Pardridge WM: Imaging brain amyloid of Alzheimer disease in vivo in transgenic mice with an Aβ peptide radiopharmaceutical. J Cereb Blood Flow Metab 22: 223-231, 2002.
98. Pardridge WM, Kang YS, Buciak JL and Yang J: Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood-brain barrier in vivo in the primate. Pharm Res 12: 807-816, 1995.
99. Boado RJ, Zhang Y, Wang Y and Pardridge WM: Engineering and expression of a chimeric transferrin receptor monoclonal antibody for blood-brain barrier delivery in the mouse. Biotechnol Bioeng 102: 1251-1258, 2009.
100. Liu Q, Zerbinatti CV, Zhang J, Hoe HS, Wang B, Cole SL, Herz J, Muglia L and Bu G: Amyloid precursor protein regulates brain apolipoprotein E and cholesterol metabolism through lipoprotein receptor LRP1. Neuron 56: 66-78, 2007.
101. Gaillard PJ, Visser CC and de Boer AG: Targeted delivery across the blood-brain barrier. Expert Opin Drug Deliv 2: 299-309, 2005.
102. Karkan D, Pfeifer C, Vitalis TZ, Arthur G, Ujiie M, Chen Q, Tsai S, Koliatis G, Gabathuler R and Jefferies WA: A unique carrier for delivery of therapeutic compounds beyond the blood-brain barrier. PLoS One 3: e2469, 2008.
103. Bertrand Y, Currie JC, Poirier J, Demeule M, Abulrob A, Fatehi D, Stanimirovic D, Sartelet H, Castaigne JP and Beliveau R: Influence of glioma tumour microenvironment on the transport of ANG1005 via low-density lipoprotein receptor-related protein 1. Br J Cancer 105: 1697-1707, 2011.
104. Muruganandam A, Tanha J, Narang S and Stanimirovic D: Selection of phage-displayed llama single-domain antibodies that transmigrate across human blood-brain barrier endothelium. FASEB J 16: 240-242, 2002.
105. Tanha J, Muruganandam A and Stanimirovic D: Phage display technology for identifying specific antigens on brain endothelial cells. Methods Mol Med 89: 435-449, 2003.
106. Abulrob A, Sprong H, Van Bergen en Henegouwen P and Stanimirovic D: The blood-brain barrier transmigrating single domain antibody: mechanisms of transport and antigenic epitopes in human brain endothelial cells. J Neurochem 95: 1201-1214, 2005
107. Pardridge WM: Biopharmaceutical drug targeting to the brain. J Drug Target 18: 157-167, 2010.
108. Salahuddin TS, Johansson BB, Kalimo H and Olsson Y: Structural changes in the rat brain after carotid infusions of hyperosmolar solutions. An electron microscopic study. Acta Neuropathol 77: 5-13, 1988.
109. Zhou QH, Boado RJ, Lu JZ, Hui EK and Pardridge WM: Monoclonal antibody-glial-derived neurotrophic factor fusion protein penetrates the blood-brain barrier in the mouse. Drug Metab Dispos 38: 566-572, 2010.
110. Zhou QH, Hui EK, Lu JZ, Boado RJ and Pardridge WM: Brainpenetrating IgG-erythropoietin fusion protein is neuroprotective following intravenous treatment in Parkinson's disease in the mouse. Brain Res 1382: 315-320, 2011.
111. Zhou QH, Boado RJ, Hui EK, Lu JZ and Pardridge WM: Brainpenetrating tumor necrosis factor decoy receptor in the mouse. Drug Metab Dispos 39: 71-76, 2011.
112. Boado RJ, Zhang Y, Zhang Y and Pardridge WM: Genetic engineering, expression, and activity of a fusion protein of a human neurotrophin and a molecular Trojan horse for delivery across the human blood-brain barrier. Biotechnol Bioeng 97: 1376-1386, 2007.
113. Boado RJ, Zhou QH, Lu JZ, Hui EK and Pardridge WM: Pharmacokinetics and brain uptake of a genetically engineered bifunctional fusion antibody targeting the mouse transferrin receptor. Mol Pharm 7: 237-244, 2010.
114. Lu JZ, Hui EK, Boado RJ and Pardridge WM: Genetic engineering of a bifunctional IgG fusion protein with iduronate-2-sulfatase. Bioconjug Chem 21: 151-156, 2010.
115. Ohshima-Hosoyama S, Simmons HA, Goecks N, Joers V, Swanson CR, Bondarenko V, Velotta R, Brunner K, Wood LD, Hruban RH and Emborg ME: A monoclonal antibody-GDNF fusion protein is not neuroprotective and is associated with proliferative pancreatic lesions in Parkinsonian monkeys. PLoS One 7: e39036, 2012.
116. Boado RJ, Zhang Y, Zhang Y, Xia CF and Pardridge WM: Fusion antibody for Alzheimer's disease with bidirectional transport across the blood-brain barrier and Aβ fibril disaggregation. Bioconjug Chem 18: 447-455, 2007.
117. Yu YJ, Zhang Y, Kenrick M, Hoyte K, Luk W, Lu Y, Atwal J, Elliott JM, Prabhu S, Watts RJ and Dennis MS: Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Transl Med 3: 84ra44, 2011.
118. Couch JA, Yu YJ, Zhang Y, Tarrant JM, Fuji RN, Meilandt WJ, Solanoy H, Tong RK, Hoyte K, Luk W, Lu Y, Gadkar K, Prabhu S, Ordonia BA, Nguyen Q, Lin Y, Lin Z, Balazs M, Scearce-Levie K, Ernst JA, Dennis MS and Watts RJ: Addressing safety liabilities of TfR bispecific antibodies that cross the blood-brain barrier. Sci Transl Med 5: 183ra57, 1-12, 2013.
119. Watts RJ and Dennis MS: Bispecific antibodies for delivery into the brain. Curr Opin Chem Biol 17: 393-399, 2013.
120. Niewoehner J, Bohrmann B, Collin L, Urich E, Sade H, Maier P, Rueger P, Stracke JO, Lau W, Tissot AC, Loetscher H, Ghosh A and Freskgard PO: Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Neuron 81: 49-60, 2014.
121. Bell RD and Ehlers MD: Breaching the blood-brain barrier for drug delivery. Neuron 81: 1-3, 2014.
122. Bohrmann B, Baumann K, Benz J, Gerber F, Huber W, Knoflach F, Messer J, Oroszlan K, Rauchenberger R, Richter WF, Rothe C, Urban M, Bardroff M, Winter M, Nordstedt C and Loetscher H: Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β. J Alzheimers Dis 28: 49-69, 2012.